Compound Evidence File
#EC-2026-0294
NPP
Filed under Injectable Oils. The bureau holds 80 laboratory returns for this compound from 26 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
26 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Apr 2026 | 13 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 28 Mar 2026 | 7 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 10.0 | 10.0 | 10.0 | 28 May 2026 | 13 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Mar 2026 | 25 Mar 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 9.9 | 9.9 | 10.0 | 13 Jan 2026 | 23 Jun 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Apr 2026 | 13 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 6 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 6 May 2026 | 9 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 21 Feb 2026 | 21 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Dec 2025 | 24 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 21 Mar 2026 | 13 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 9.9 | 10 Nov 2025 | 12 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Mar 2026 | 10 Apr 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 8.8 | 7.6 | 10.0 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 2 | 8.8 | 8.0 | 9.7 | 23 May 2026 | 23 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.6 | 7.3 | 10.0 | 24 May 2026 | 24 May 2026 |
| Peptide-SCASE #VI-2026-0111 | X | 4 | 8.6 | 7.1 | 9.8 | 17 Dec 2024 | 25 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.5 | 6.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.3 | 8.0 | 8.7 | 24 May 2026 | 24 May 2026 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 8.0 | 8.0 | 8.0 | 24 Apr 2025 | 24 Apr 2025 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 7.6 | 7.6 | 7.6 | 17 Dec 2024 | 17 Dec 2024 |
| DeuschemCASE #VI-2026-0004 | X | 2 | 4.5 | 3.2 | 5.7 | 21 May 2025 | 25 May 2026 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 2.7 | 2.7 | 2.7 | 28 Mar 2025 | 28 Mar 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.0 | 0.0 | 0.0 | 25 Apr 2025 | 25 Apr 2025 |
Open any subject to view the batch-level evidence for NPP alone.